Tag Archive: Center for Childhood Cancer Research

Jun 27 2018

Stephen P. Hunger, MD, Receives Prestigious George R. Buchanan Lectureship Award

Stephen P. Hunger, MD

Stephen P. Hunger, MD, has received numerous honors throughout his decorated career. However, winning the George R. Buchanan Lectureship Award from the American Society of Pediatric Hematology/Oncology (ASPHO) had particularly special meaning to the chief of the Division of Oncology and director of the Center for Childhood Cancer Research at Children’s Hospital of Philadelphia.

Recognized internationally in the field of pediatric leukemia clinical care and research, Dr. George R. Buchanan— past president of ASPHO and a renowned pediatric hematology physician-researcher — was very supportive of Dr. Hunger early in his career.

Read the rest of this entry >>

Dec 30 2016

CHOP Research In the News: Rose Bowl Parade, Asthma, Cardiac Imaging, Pediatric Leukemia, Immune Response

CHOP Research In the NewsThe end of the year has come up fast, and so have important advances in pediatric research at Children’s Hospital of Philadelphia. This week’s In the News starts off with a celebration of two remarkable patients and their dedicated pediatric oncologist.

Read the rest of this entry >>

Dec 23 2014

Pediatric Leukemia Expert Named CCCR Director

Hunger,Stephen_blogStephen P. Hunger, MD, a nationally prominent specialist in children’s cancer, has been named the new director of the Center for Childhood Cancer Research (CCCR) and chief of the Division of Oncology.

Read the rest of this entry >>

May 6 2014

Blocking Paths to Resistance to T Cell Therapy for B-ALL

B-ALLCHOP’s Center for Childhood Cancer Research (CCCR), has begun a unique collaboration that will contribute to scientific understanding of how immunotherapy can improve the survival of children with B cell acute lymphoblastic leukemia (B-ALL) that resists standard therapy.

Read the rest of this entry >>

Jan 24 2013

Study Shows Neuroblastoma Evolves Rapidly, Limiting Treatment Targets

neuroblastomaA recent genomic study of neuroblastoma reinforces the challenges of treating the most aggressive forms of this disease. Contrary to expectations, the researchers found relatively few recurrent gene mutations — mutations that would suggest new targets for neuroblastoma treatment. Instead, the investigators have refocused on how neuroblastoma tumors evolve in response to medicine and other factors.

Read the rest of this entry >>